Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Bio-Rad Laboratories, Inc.: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Bio-Rad Laboratories, Inc.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses: Bio-Rad Laboratories, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.56 times its estimated earnings per share for the ongoing year.
  • Most analysts recommend that the stock should be sold or reduced.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The group usually releases earnings worse than estimated.

Rating Financials

Bio-Rad Laboratories, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Bio-Rad Laboratories, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bio-Rad Laboratories, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bio-Rad Laboratories, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bio-Rad Laboratories, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.04B
BBB
-
177B
BBB
120B
BBB
61.69B
AA
50.64B
A
48.16B
AAA
32.62B
BBB
28.17B
A
25.69B
AAA
21.33B
AA
Average 57.48B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. Ratings Bio-Rad Laboratories, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!